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Abstract 
Influenza viruses seemed to be important cause of severe AECOPD. But it is not clear to the end 
pathogenesis and clinical features of severe AECOPD during seasonal epidemics of flu.  
The aim was to study the features of clinical course, severity of lung disorders in patients with severe 
AECOPD during the 2016–2017 Influenza epidemic and to find possible predictors of lethality during 
severe AECOPD in this period. 
It was a retrospective observational study using medical histories of patients died from severe AECOPD 
with detected and suspected (according to anamnestic, epimiological and clinical data) Influenza 
A(H1N1), which were hospitalized in intensive care units in epidemic period of 2016–2017.  
It was found that patients admitted to the doctor very late, worsening started with febrile and hyperfebrile 
temperature before hospitalization, great weakness, dry cough; among clinical symptoms acute 
respiratory failure prevailed; additional symptoms were cachexia and decompensation of cardiovascular 
comorbidity.  
Other features of lethal severe AECOPD were very low parameters of external breathing. According to 
chest CT-scans most died patients had severe changes of bronchi and lung parenchyma such as chronic 
bronchitis, lung emphysema, bronchoecstasies and bulls. One of the most severe complication was 
pneumothorax.  
The mortality of patients with severe AECOPD depends on too late hospitalization, lack of anti-
inflammatory treatment and absence of preventive vaccinations. Severe lung function disorders in 
anamnesis are the most significant predictor of mortality in patients with COPD during epidemic seasons 
and should be indicators of early intensive treatment with oxygenation. The key point in the treatment of 
virus-associated severe AECOPD is early, sufficient and adequate oxygen therapy taking into account the 
high risk of pneumothoraxes which significantly aggravates the course of disease. 
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1. Introduction 
Viral infections of the respiratory tract are the commonest disease syndrome in humans. A 
number of different viruses can infect the human respiratory tract. Most of them cause self-
limiting illnesses such as the common cold or acute bronchitis. The severity of illness depends 
on the particular virus and on host factors. In patients with airway diseases such as chronic 
obstructive pulmonary disease (COPD), the morbidity caused by respiratory virus infection is 
considerably greater. Among respiratory viruses, influenza has the greatest impact in terms of 
both the morbidity and mortality that it causes. Although influenza affects all age groups, 
much of the morbidity and mortality are concentrated in high-risk groups such as the elderly 
and those with concomitant disease, particularly cardiovascular and pulmonary disorders [1].  
The mortality and utilization of healthcare resources associated with influenza is concentrated 
in the elderly and those with coexisting disease such as COPD. Increasing use of vaccination 
and the development of new antiviral drugs hold out hope that the burden of disease associated 
with influenza can be reduced. However the constant emergence of new influenza strains serve 
as warnings that influenza will remain a serious pathogen for the foreseeable future [1]. 
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) cause significant 
morbidity, mortality, and an inexorable decline of lung function [2, 3]. AECOPD can be caused 
by a number of factors but the commonest cause is infection of the tracheobronchial tree. 
Historically COPD exacerbations have been considered as being predominantly caused by 
bacteria, however recent evidence has suggested that respiratory viruses are associated with 
40%–60% of COPD exacerbations [4]. Data from developed countries have shown viruses to be 
important causes of severe AECOPD [2]. But it pathogenesis and clinical features of severe 
AECOPD during seasonal epidemics of flu are not quit clear to the end. 
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That is why the aim was to study the features of clinical 
course, severity of lung disorders in patients with severe 
AECOPD during the 2016–2017 Influenza epidemic and to 
find possible predictors of lethality during severe AECOPD in 
this period. 
 
2. Materials and methods 
Study design is a retrospective observational study. Materials 
include medical histories of 35 patients (age from 65 to 75 
years old, male – 30 (85,7%)) died from severe AECOPD 
with detected and suspected (according to anamnestic, 
epimiological and clinical data) Influenza A(H1N1), which 
were hospitalized in intensive care units of several city and 
regional clinics in Dnipro, Ukraine in epidemic period of 
2016–2017.  
We analyzed results of such methods of investigator as 
general inspection, pulsoxymetria, spirometry (last data 
before hospitalization or during hospitalization if possible) 
with diagnosing of main parameter: forced exhaled volume 
for the first second after using of bronchodilatator (FEV1 
(post)), general and biochemical blood test, microbiological 
sputum analysis, nasopharyngeal swabs on Influenza A(H1N1) 
(if possible), determination of Influenza A(H1N1)-California 
RNA (if possible).  
Statistical processing of the results of research carried out 
using the methods of biometric analysis, implemented in 
software packages EXCEL-2003 (№ 74017-641-9475201-
57075) and STATISTICA 6.0 (№ 31415926535897) [6]. 
 
3. Results and discussion 
On admission the status of all patients of the group was 
reported as serious. After verification of severe AECOPD and 
the initial survey all patients were assigned to the adequate 
nebulizer (which included high doses of IGCS in combination 
with bronchodilatators) and antibacterial treatment (which 
included protected aminopenicillins (amoxicillin/clavulanic 
acid or ampicillin/sulbactam) or cephalosporins of III 
generation (ceftriaxone) in combination with macrolides, as 
an alternative therapy used combination of fluoroquinolones 
of III or IV generation and "protected" aminopenicillin or 
cephalosporin of III generation).  
During analyzing of anamnesis at died patients with severe 
AECOPD it was found that patients admitted to the doctor 
very late. Average length of disease before hospitalization 
was 5, 6±0,4 days. At most of them (in 32 (91, 4%) patients) 
this worsening started with febrile and hyperfebrile 
temperature before hospitalization, great weakness, dry 
cough.  
Among clinical symptoms acute respiratory failure prevailed. 
It was almost refractory for oxygen therapy (mean saturation 
was 91, 3±1,9%). Additional symptoms were cachexia (in 32 
(91, 4%) cases), decompensation of cardiovascular 
comorbidity (in 18 (51, 4%) cases).  
Very low parameters of external breathing were other features 
of lethal severe AECOPD. According to medical cards it was 
impossible to do spirometry for these patients in the hospital 
because of severe state, but from anamnesis and historical 
documents (if possible) it was known, that average 
FEV1(post) was 34,6±1,4% pred. before hospitalization 
(during 0,5–1 year period), which corresponds to GOLD 3-4. 
Spirometry with minimal and maximal values are presented 
on the picture 1A and 1B corresponding. 
 
  
A     B 
 
Picture 1: Historical post-dose spirometric test of patients died from AECOPD with minimal (A) and maximal (B) parameters of FEV1 (post) 
 
During analyzing if chest CT-scans it was find out that most 
died patients had severe changes of bronchi and lung 
parenchyma. Like on presented pictures patients had X-ray 
symptoms of chronic bronchitis, lung emphysema, 
bronchoecstasies and bulls (picture 2A and 2B). 
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A   B 
 
Picture 2: Historical chest CT-scans of patients died from 
AECOPD: chronic bronchitis, lung emphysema, bronchoecstasies 
(A) and bulls (B) 
 
Pneumothorax was one of the most severe complication, 
which happened in 17 (56,7%) cases during hospitalization 
because of severe AECOPD. On picture 3 historical CT-scan 
slides of the patient died from AECOPD in January 2017 are 
presented. Patient had giant bull and pneumothorax during 
staying in the intensive care unit, which aggravated greatly 
the severity of the patient (picture 3A and 3B). 
 
 
A   B 
 
Picture 3: Historical chest CT-scan (A) with big bull and simple X-
ray with pneumothorax (B) of the patient died from AECOPD 
 
On autopsy there were found such pathomorphological signs 
as hemorrhagic changes on trachea and bronchi, severe lung 
emphysema with bulls, pneumothoraxes (picture 4A, B). 
 
 
A   B 
 
Picture 4: Lung macropreparation with emphysema (A) and big 
bulls (B) of the patient died from AECOPD 
 
Microbiological findings were positive only in 5 (14,3%) 
cases at patients with severe virus-associated AECOPD. 
Multiresistant Pseudomonas aeruginosa (n=2) and 
multiresistant Klebsiella pneumoniae (n=3) were found in 
sputum and after autopsy in summary. 
 
4. Conclusions 
1. The mortality of patients with severe AECOPD depends 
on too late hospitalization, lack of anti-inflammatory 
treatment and absence of preventive vaccinations.  
2. Severe lung function disorders in anamnesis (FEV1(post) 
less than 30% pred. and low saturation (less than 95%) 
are the most significant predictors of mortality in patients 
with COPD during epidemic seasons and should be 
indicators of early intensive treatment with oxygenation.  
3. The key point in the treatment of virus-associated severe 
AECOPD is early, sufficient and adequate oxygen 
therapy taking into account the high risk of 
pneumothoraxes which significantly aggravates the 
course of disease. 
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